Brief: Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi
03/03/2026 22:20
March 4 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI GROUP IS ELIGIBLE TO RECEIVE AN UPFRONT PAYMENT OF US$135 MILLION SALES MILESTONE PAYMENTS OF UP TO US$1,395 MILLION Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes